- $39.25m
- -$5.63m
- $6.81m
- 51
- 37
- 56
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.54 | ||
| Price to Tang. Book | 0.85 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -51.46% | ||
| Return on Equity | -42.73% | ||
| Operating Margin | -424.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.21 | 74.55 | 97.89 | 34.22 | 6.81 | 3.88 | 1.5 | 179.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -18.85 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Directors
- Dwight Egan CHM (67)
- Brian Brown CFO (45)
- Reed Benson GCN (74)
- Eugene Durenard IND (51)
- Edward Murphy IND (56)
- James Nelson IND (68)
- Richard Serbin IND (76)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 18th, 2013
- Public Since
- July 12th, 2017
- No. of Shareholders
- 154
- No. of Employees
- 155
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 31,911,002
- Address
- 4049 S Highland Dr, SALT LAKE CITY, 84124-1664
- Web
- http://codiagnostics.com/
- Phone
- +1 8012789769
- Auditors
- Tanner LLC
Upcoming Events for CODX
Q4 2024 Co-Diagnostics Inc Earnings Release
Similar to CODX
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Co-Diagnostics share price?
As of Today at 20:02 UTC, shares in Co-Diagnostics are trading at $1.23. This share price information is delayed by 15 minutes.
How has the Co-Diagnostics share price performed this year?
Shares in Co-Diagnostics last closed at $1.23 and the price had moved by +13.89% over the past 365 days. In terms of relative price strength the Co-Diagnostics share price has underperformed the S&P500 Index by -14.89% over the past year.
What are the analyst and broker recommendations for Co-Diagnostics?
The overall consensus recommendation for Co-Diagnostics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Co-Diagnostics dividend yield?
Co-Diagnostics does not currently pay a dividend.
Does Co-Diagnostics pay a dividend?
Co-Diagnostics does not currently pay a dividend.
When does Co-Diagnostics next pay dividends?
Co-Diagnostics does not currently pay a dividend.
How do I buy Co-Diagnostics shares?
To buy shares in Co-Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Co-Diagnostics?
As of the previous close price of $1.23, shares in Co-Diagnostics had a market capitalisation of $39.25m.
Where are Co-Diagnostics shares listed?
Here are the trading details for Co-Diagnostics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CODX
What kind of share is Co-Diagnostics?
Based on an overall assessment of its quality, value and momentum Co-Diagnostics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Co-Diagnostics share price forecast for 2024?
The analyst consensus target price for shares in Co-Diagnostics is $1.50. That is 21.95% above the last closing price of $1.23.
Analysts covering Co-Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of -$1.23 for the next financial year.
Find out moreWhat is the trend in the Co-Diagnostics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Co-Diagnostics. Over the past six months, its share price has outperformed the S&P500 Index by +0.36%.
As of the last closing price of $1.23, shares in Co-Diagnostics were trading -0.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Co-Diagnostics PE Ratio?
The Co-Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Co-Diagnostics?
Co-Diagnostics' management team is headed by:
- Dwight Egan - CHM
- Brian Brown - CFO
- Reed Benson - GCN
- Eugene Durenard - IND
- Edward Murphy - IND
- James Nelson - IND
- Richard Serbin - IND